Journey Medical Corp (NASDAQ:DERM)’s traded shares stood at 0.35 million during the last session, with the company’s beta value hitting 0.90. At the close of trading, the stock’s price was $5.35, to imply a decrease of -2.37% or -$0.13 in intraday trading. The DERM share’s 52-week high remains $8.11, putting it -51.59% down since that peak but still an impressive 46.73% since price per share fell to its 52-week low of $2.85. The company has a valuation of $111.76M, with an average of 97100.0 shares in intraday trading volume over the past 10 days and average of 96.93K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Journey Medical Corp (DERM), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give DERM a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Journey Medical Corp (NASDAQ:DERM) trade information
After registering a -2.37% downside in the last session, Journey Medical Corp (DERM) has traded red over the past five days. The 5-day price performance for the stock is -7.44%, and -1.65% over 30 days. With these gigs, the year-to-date price performance is -7.12%. Short interest in Journey Medical Corp (NASDAQ:DERM) saw shorts transact 66232.0 shares and set a 0.46 days time to cover.
Journey Medical Corp (DERM) estimates and forecasts
Looking at statistics comparing Journey Medical Corp share performance against respective industry, we note that the company has underperformed competitors. Journey Medical Corp (DERM) shares are 13.83% up over the last 6 months, with its year-to-date growth rate lower than industry average at -385.71% against 16.60%. The rating firms project that company’s revenue will shrink -28.36% compared to the previous financial year.
Revenue forecast for the current quarter as set by 4 analysts is 14.21M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 12.44M.Earnings reports from the last fiscal year show that sales brought in 15.26M and 13.03M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -6.84% before dropping -4.50% in the following quarter.
DERM Dividends
Journey Medical Corp has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Journey Medical Corp (NASDAQ:DERM)’s Major holders
Journey Medical Corp insiders hold 30.48% of total outstanding shares, with institutional holders owning 24.86% of the shares at 35.76% float percentage. In total, 24.86% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 0.31 million shares (or 1.5703% of shares), all amounting to roughly $1.75 million.
The next major institution holding the largest number of shares is CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. with 0.29 million shares, or about 1.4929% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $1.66 million.
